MX2011005537A - Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueadores del canal de calcio. - Google Patents

Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueadores del canal de calcio.

Info

Publication number
MX2011005537A
MX2011005537A MX2011005537A MX2011005537A MX2011005537A MX 2011005537 A MX2011005537 A MX 2011005537A MX 2011005537 A MX2011005537 A MX 2011005537A MX 2011005537 A MX2011005537 A MX 2011005537A MX 2011005537 A MX2011005537 A MX 2011005537A
Authority
MX
Mexico
Prior art keywords
pyrrol
octahydrocyclopenta
trifluoromethyl
methyl
sulfonyl
Prior art date
Application number
MX2011005537A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Stewart
Xenia Searle
Daria Darczak
Ming YEUNG
Stanley Didomenico
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42124348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011005537(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2011005537A publication Critical patent/MX2011005537A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2011005537A 2008-11-26 2009-11-25 Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueadores del canal de calcio. MX2011005537A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11799508P 2008-11-26 2008-11-26
PCT/US2009/065847 WO2010062927A2 (en) 2008-11-26 2009-11-25 Novel substituted octahydrocyclopenta(c)pyrrol-4-amines as calcium channel blockers

Publications (1)

Publication Number Publication Date
MX2011005537A true MX2011005537A (es) 2011-06-21

Family

ID=42124348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011005537A MX2011005537A (es) 2008-11-26 2009-11-25 Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueadores del canal de calcio.

Country Status (23)

Country Link
US (1) US8129417B2 (cg-RX-API-DMAC7.html)
EP (1) EP2367790A2 (cg-RX-API-DMAC7.html)
JP (1) JP2012509940A (cg-RX-API-DMAC7.html)
KR (1) KR20110091784A (cg-RX-API-DMAC7.html)
CN (1) CN102292319A (cg-RX-API-DMAC7.html)
AR (1) AR074226A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009319796A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921184A2 (cg-RX-API-DMAC7.html)
CA (1) CA2742350A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011001176A1 (cg-RX-API-DMAC7.html)
CO (1) CO6382118A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110304A (cg-RX-API-DMAC7.html)
EC (1) ECSP11011160A (cg-RX-API-DMAC7.html)
IL (1) IL212484A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011005537A (cg-RX-API-DMAC7.html)
NZ (1) NZ592507A (cg-RX-API-DMAC7.html)
PA (1) PA8850301A1 (cg-RX-API-DMAC7.html)
PE (1) PE20110833A1 (cg-RX-API-DMAC7.html)
RU (1) RU2011126215A (cg-RX-API-DMAC7.html)
TW (1) TW201028378A (cg-RX-API-DMAC7.html)
UY (1) UY32261A (cg-RX-API-DMAC7.html)
WO (1) WO2010062927A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103538B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062927A2 (en) 2008-11-26 2010-06-03 Abbott Laboratories Novel substituted octahydrocyclopenta(c)pyrrol-4-amines as calcium channel blockers
EP2378885A4 (en) * 2008-12-12 2013-01-02 Univ Vanderbilt 3.3.0 BICYCLIC GLYT1 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2011115813A1 (en) * 2010-03-18 2011-09-22 Abbott Laboratories Lactam acetamides as calcium channel blockers
US8796470B2 (en) 2010-05-25 2014-08-05 Abbvie Inc. Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators
WO2011149995A1 (en) * 2010-05-25 2011-12-01 Abbott Laboratories Novel substituted octahydrocyclopenta [c]pyrrol-4-amines as calcium channel blockers
FR2976285B1 (fr) * 2011-06-08 2013-05-24 Servier Lab Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent
WO2013049164A1 (en) 2011-09-29 2013-04-04 Abbvie Inc. SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS
WO2013049174A1 (en) 2011-09-29 2013-04-04 Abbvie Inc. Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers
US9029361B2 (en) 2012-12-12 2015-05-12 Abbvie Inc. Agents for treating pain and uses thereof
CN107849009B (zh) * 2015-10-13 2021-03-02 四川海思科制药有限公司 一种八氢环戊二烯并[c]吡咯衍生物及其制备方法和在医药上的用途
CN118684652A (zh) * 2017-09-11 2024-09-24 克鲁松制药公司 SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
SG11202008113RA (en) 2018-03-05 2020-09-29 Arcus Biosciences Inc Arginase inhibitors
CA3214469A1 (en) * 2021-04-01 2022-10-06 Ono Pharmaceutical Co., Ltd. Abhd6 antagonist
KR20240046089A (ko) 2022-09-30 2024-04-08 오노 야꾸힝 고교 가부시키가이샤 Abhd6 길항제를 함유하는 약학 조성물
TW202421635A (zh) 2022-09-30 2024-06-01 日商小野藥品工業股份有限公司 Abhd6拮抗劑
JP2024052624A (ja) * 2022-09-30 2024-04-11 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニストを含有する医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0278659A (ja) 1988-09-12 1990-03-19 Shionogi & Co Ltd アザビシクロアルカン類化合物
DE60011755T2 (de) * 1999-04-07 2005-06-30 The University Of Virginia Patent Foundation Calciumkanalblocker als antikrebsmittel
US8163769B2 (en) * 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
US7223754B2 (en) 2003-03-10 2007-05-29 Dynogen Pharmaceuticals, Inc. Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
JP2006514964A (ja) * 2003-03-12 2006-05-18 アボット・ラボラトリーズ 抗菌剤としてのナフチリジン誘導体
US7381738B2 (en) * 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7230022B2 (en) * 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
JP2008507543A (ja) * 2004-07-22 2008-03-13 グラクソ　グループ　リミテッド 抗細菌剤
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2006236625A1 (en) 2005-04-19 2006-10-26 Merck & Co., Inc. N-alkyl-azacycloalkyl NMDA/NR2B antagonists
US8044069B2 (en) * 2008-10-02 2011-10-25 Abbott Laboratories Compounds as calcium channel blockers
WO2010062927A2 (en) 2008-11-26 2010-06-03 Abbott Laboratories Novel substituted octahydrocyclopenta(c)pyrrol-4-amines as calcium channel blockers
EP2378885A4 (en) 2008-12-12 2013-01-02 Univ Vanderbilt 3.3.0 BICYCLIC GLYT1 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF

Also Published As

Publication number Publication date
CN102292319A (zh) 2011-12-21
AU2009319796A8 (en) 2011-06-30
NZ592507A (en) 2013-08-30
WO2010062927A3 (en) 2010-07-22
CO6382118A2 (es) 2012-02-15
CL2011001176A1 (es) 2011-11-11
PE20110833A1 (es) 2011-12-21
PA8850301A1 (es) 2010-07-27
WO2010062927A2 (en) 2010-06-03
AR074226A1 (es) 2010-12-29
US8129417B2 (en) 2012-03-06
IL212484A0 (en) 2011-06-30
UY32261A (es) 2010-06-30
ZA201103538B (en) 2012-11-28
US20100130558A1 (en) 2010-05-27
KR20110091784A (ko) 2011-08-12
AU2009319796A1 (en) 2010-06-03
CA2742350A1 (en) 2010-06-03
RU2011126215A (ru) 2013-01-10
ECSP11011160A (es) 2011-07-29
JP2012509940A (ja) 2012-04-26
EP2367790A2 (en) 2011-09-28
CR20110304A (es) 2011-10-27
BRPI0921184A2 (pt) 2018-03-13
TW201028378A (en) 2010-08-01

Similar Documents

Publication Publication Date Title
MX2011005537A (es) Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueadores del canal de calcio.
US8741899B2 (en) (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof
US8815869B2 (en) Lactam acetamides as calcium channel blockers
CA3015482A1 (en) Heteroaryl inhibitors of pad4
US8796470B2 (en) Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators
US8044069B2 (en) Compounds as calcium channel blockers
AU2016270677B2 (en) 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
US8691865B2 (en) Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers
EP4110317B1 (en) Kcnt1 inhibitors and methods of use
US8648074B2 (en) Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers
WO2016100349A2 (en) Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
US8669255B2 (en) Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers

Legal Events

Date Code Title Description
GB Transfer or rights